Who makes GSK2269557 500 µg?

GSK2269557 500 µg is developed by GlaxoSmithKline.

What development phase is GSK2269557 500 µg in?

GSK2269557 500 µg is in Phase 1.

Last reviewed 2026-05-14 · How we verify

GSK2269557 500 µg

GlaxoSmithKline · Phase 1 active Small molecule

At a glance

Generic name	GSK2269557 500 µg
Sponsor	GlaxoSmithKline
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GSK2269557 500 µg CI brief — competitive landscape report
GSK2269557 500 µg updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI